Table 2.
Top five enriched canonical pathways in drug-treated cells compared with mock-treated cells
| Drug | Ingenuity canonical pathways | P value | Overlapping rate (%) (enriched gene no./total no.) | |
|---|---|---|---|---|
| DAC | 1 | Interferon signaling | 4.47E−07 | 38.2% (13/34) |
| 2 | Hepatic fibrosis/hepatic stellate cell activation | 2.68E−05 | 16.7% (30/180) | |
| 3 | TREM1 signaling | 5.79E−04 | 20.0% (14/70) | |
| 4 | Activation of IRF by cytosolic pattern recognition receptors | 1.02E−03 | 20.7% (12/58) | |
| 5 | Granulocyte adhesion and diapedesis | 1.06E−03 | 14.7% (24/163) | |
| OR-2003 | 1 | Interferon signaling | 3.72E−06 | 35.3% (12/34) |
| 2 | Hepatic fibrosis/hepatic stellate cell activation | 3.23E−05 | 16.7% (30/180) | |
| 3 | TREM1 signaling | 6.39E−04 | 20.0% (14/70) | |
| 4 | Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis | 1.02E−03 | 12.8% (38/298) | |
| 5 | Activation of IRF by cytosolic pattern recognition receptors | 1.12E−03 | 20.7% (12/58) | |
| OR-2100 | 1 | Interferon signaling | 4.40E−07 | 38.2% (13/34) |
| 2 | Hepatic fibrosis/hepatic stellate cell activation | 6.66E−05 | 16.1% (29/180) | |
| 3 | TREM1 signaling | 5.70E−04 | 20.0% (14/70) | |
| 4 | Activation of IRF by cytosolic pattern recognition receptors | 1.01E−03 | 20.7% (12/58) | |
| 5 | Role of macrophages, fibroblasts, and endothelial cells in rheumatoid arthritis | 1.56E−03 | 12.4% (37/298) |